Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB565 in Advanced Solid Tumors
NCT07545265Phase 2Recruiting
- Sponsor
- Kelun-Biotech
- Start
- Aug 2026
- Primary completion
- Mar 2029
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
A Phase 2 trial of SKB565 in solid tumor, sponsored by Kelun-Biotech. Started Aug 2026; status: recruiting.
02
Drugs
SKB565
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07545265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07545265.